The 2016 revision of the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues is characterized by a closer integration of morphology and molecular genetics. Notwithstanding, the myelodysplastic syndrome (MDS) with isolated del(5q) remains so far the only MDS subtype defined by a genetic abnormality.
Dr. Abdulraheem Yacoub talks with Leigh Clark about MDS-MPN overlap. He includes how molecular testing is used in determining treatment options.
He also discusses the newly approved drug, Luspatercept, for the treatment of MDS and MDS-MPN overlap syndromes.
According to the United States Centers for Disease Control and Prevention (CDC), coronaviruses are a large family of viruses that are common in humans and can cause illnesses ranging from mild respiratory infections like the common cold to serious illnesses, such as pneumonia or Severe Acute Respiratory Syndrome (SARS). The novel coronavirus (COVID-19) has now been detected in more than 100 countries, including the US.
Why are older adults and people with chronic health conditions at higher risk?
Here is a discussion of the recent approval of Luspatercept with Dr. Amit Verma, Director of the Division of Hematologic Malignancies and a Professor of Oncology at the Albert Einstein College of Medicine in New York City. He explains the results of clinical trials and describes which MDS patients have the best response to this medication.
#MDS #treatingMDS
Dr. Gustavo Rivero describes strategies for the management of Low-Risk MDS, or Myelodysplastic Syndromes. He details supportive care for these patients, including transfusions and iron overload therapies.
Dr Vu Duong explains risk classifications for MDS. He dives into IPSS and IPSS-R scores, focused on helping patients to understand the meanings of high-risk and low-risk MDS.